Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 2 - Episode 5
What clinical data support the use of trabectedin in patients with myxoid liposarcoma?
There is data from our colleagues in Milan, the Italian Sarcoma Group and the National Cancer Institute in Milan where they have looked at a series of patients specifically with mixoid liposarcoma. In the earlier days of the investigations with this drug have shown that the probability that you will get volumetric response, RECIST responses is very high, at least greater than 50%. That has clearly born out in the subsequent trials in the vast experience in the public domain, looking at trabectedin in various types of sarcomas. Mixoid liposarcoma now is recognized as one of the more sensitive subsets to Yondelis or trabectedin therapy.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.